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Abstract
Background: Multidrug resistant Acinetobacter baumannii (MDRAB) is an important nosocomial pathogen usually
susceptible to carbapenems; however, growing number of imipenem resistant MDRAB (IR-MDRAB) poses further clinical
challenge. The study was designed to identify the risk factors for appearance of IR-MDRAB on patients formerly with
imipenem susceptible MDRAB (IS-MDRAB) and the impact on clinical outcomes.
Methodology/Principal Findings: A retrospective case control study was carried out for 209 consecutive episodes of IS-
MDRAB infection or colonization from August 2001 to March 2005. Forty-nine (23.4%) episodes with succeeding clinical
isolates of IR-MDRAB were defined as the cases and 160 (76.6%) with all subsequent clinical isolates of IS-MDRAB were
defined as the controls. Quantified antimicrobial selective pressure, ‘‘time at risk’’, severity of illness, comorbidity, and
demographic data were incorporated for multivariate analysis, which revealed imipenem or meropenem as the only
significant independent risk factor for the appearance of IR-MDRAB (adjusted OR, 1.18; 95% CI, 1.09 to 1.27). With selected
cases and controls matched to exclude exogenous source of IR-MDRAB, multivariate analysis still identified carbapenem as
the only independent risk factor (adjusted OR, 1.48; 95% CI, 1.14 to 1.92). Case patients had a higher crude mortality rate
compared to control patients (57.1% vs. 31.3%, p=0.001), and the mortality of case patients was associated with shorter
duration of ‘‘time at risk’’, i.e., faster appearance of IR-MDRAB (adjusted OR, 0.9; 95% CI, 0.83 to 0.98).
Conclusions/Significance: Judicious use of carbapenem with deployment of antibiotics stewardship measures is critical for
reducing IR-MDRAB and the associated unfavorable outcome.
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Introduction
Acinetobacter baumannii is an increasingly important nosocomial
pathogen with resistance to multiple antimicrobial agents [1,2].
Multidrug resistant A. baumannii (MDRAB) usually retained in vitro
susceptibility to carbapenems [3,4]; however, emergence of
imipenem resistant MDRAB (IR-MDRAB) occurred since early
90’s, which imposed a grave concern in clinical practice as IR-
MDRAB was susceptible to few drugs in vitro [5–9].
There have been many studies on risk factors for the emergence
of MDRAB [2,8–15]. Patients with carbapenem resistant strains
were compared to those with susceptible ones [9–11,14]. The role
of carbapenem might be exaggerated with this straightforward
comparison [16,17]. Other studies took hospitalized patient
cohorts as controls and risk factors identified were usually those
for nosocomial infection [15]. In addition, antimicrobial selective
pressure has never been comprehensively quantified and ‘‘time at
risk’’, the period of time at risk for emergence of resistant strains,
has seldom been soundly adjusted. Severity of illness or
comorbidities were not included for analysis in some studies
[11,13].
This case control study was designed to identify the risk factors
for the common situation of appearance of IR-MDRAB on
patients formerly with imipenem susceptible MDRAB (IS-
MDRAB). We compared two groups of patients, both with IS-
MDRAB at first. IR-MDRAB appeared later in one group but not
in the other. Time at risk, quantified antimicrobial selective
pressure, severity of illness, comorbidity and demographic data,
were incorporated into multivariate analysis. The impact of
appearance of IR-MDRAB on clinical outcomes was evaluated as
well. The study was deliberately designed for optimization of
several important methodological principles of case control studies
for risk factor analysis of antibiotic resistance, including control
group selection and adjusting for confoundings such as time at risk,




The study was approved by the ethics review board of the
Chang Gung Memorial Hospital Linkou Medical Center in
September 2008. Patient consent was not obtained because data
were analyzed anonymously.
Cases and controls
Chang Gung Memorial Hospital Linkou Medical Center is a
3000-bed university-affiliated medical center with 308 ICU beds.
Identification of A. baumannii was by conventional biochemical tests
[18]. Susceptibilities to all antimicrobial agents were determined
and interpreted according to criteria of the Clinical and
Laboratory Standards Institute (CLSI) by disk diffusion suscepti-
bility [19]. Database of microbiology laboratory between August
2001 and March 2005 was reviewed for clinical isolates of
MDRAB. Multidrug resistance was defined as resistance to
amikacin, gentamicin, piperacillin, cefepime, ceftazidime, aztreo-
nam, and ciprofloxacin. Intermediate susceptibility was considered
as resistance.
Hospitalized patients with one culture of IS-MDRAB and
subsequent cultures of MDRAB from the same body site, sampled
during the same hospitalization and at least 7 days apart, were
included. Patients with succeeding clinical isolates of IR-MDRAB
were defined as the cases. Those with all subsequent clinical
isolates of IS-MDRAB were defined as the controls. Two
hospitalizations separated by less than 30 days were taken as one
hospitalization. Blood was considered as the same body site of any
culture site, since it was possibly the invasive complication of any
infected site. Pleural effusion was taken as part of the respiratory
tract. Patients may be included for more than 1 time if they met
the inclusion criteria during different occasions, such as different
admissions or different episodes of the same admission.
Time at risk
The ‘‘time at risk’’ was defined as the time interval between
detection of first IS-MDRAB and detection of first IR-MDRAB
for case patients, and the time interval between detection of first
and last IS-MDRAB for control patients. It is the period of time at
risk for appearance of imipenem resistant strains for each
individual patient.
Demographic data and comorbidities
Age, sex, site of A. baumannii growth and comorbidities were
gathered by reviewing the medical records. Comorbidities
included hepatic dysfunction of a bilirubin concentration over
2.5 mg/dl or liver cirrhosis, renal insufficiency of a creatinine level
above 2.0 mg/dl or requirement of dialysis, chronic pulmonary
disease, cardiac disease, cerebral vascular accident, diabetes
mellitus, immune compromise, hematological or solid organ
malignancy, and surgery. Immune compromise was defined as
corticosteroid use during the hospitalization (prednisone or
equivalent over 20 mg per day for at least 2 weeks), human
immunodeficiency virus (HIV) infection or acquired immune
deficiency syndrome (AIDS), neutropenia (neutrophil count less
than 500 cells/mm3) during the time at risk, use of immunosup-
pressive agents, including chemotherapeutics, within 30 days prior
to A. baumannii growth, and concurrent hematological malignancy.
Surgical procedures were those within 30 days prior to A. baumannii
growth.
Clinical conditions and treatments
Length of ICU stay, ventilator dependence and doses and
duration of all antibacterial agents, during the period of the ‘‘time
at risk’’, were documented. Severity of illness was quantified by a
modified APACHE (Acute Physiology And Chronic Health
Evaluation) II score, recorded within 48 hours before or after
the day of first clinical isolate of IS-MDRAB [20]. Data for
APACHE II score were not all available for patients of minor
disease severity and then the missing data were ignored.
Statistical methods
All statistical analyses were performed using SPSS version 15.0.
Tests performed in univariate analysis were chi-square test or
Fisher exact tests for categorical variables and Student t test or
Mann–Whitney test for continuous variables as appropriate. The
Kolmogorov-Smirnov test or Shapiro-Wilk test was used to assess
normality as appropriate. Odds ratios (ORs) and 95% confidence
intervals (CIs) were calculated. All variables with a p value of
,0.05 in univariate analysis were included in a logistic regression
model for multivariate analysis. All tests were two-tailed, and a p
value of ,0.05 was considered significant in multivariate analysis.
Results
Risk factors for appearance of IR-MDRAB
Case control study. With review of the microbiology
laboratory database, we identified in 206 patients 209 episodes
of infection or colonization of IS-MDRAB, which were with
subsequent cultures of MDRAB. Appearance of IR-MDRAB
occurred in 49 (23.4%) episodes but not in the other 160 (76.6%).
The former were defined as the cases and the later were defined as
the controls.
For the 209 episodes, the mean age was 62620 year old,
presenting a population of seniority. Male predominated (66%)
and comorbidities were common. About 40% of them received
surgical procedures within 30 days prior to A. baumannii growth.
The ‘‘time at risk’’ ranged from 7 to 134 days, with a mean of 21.9
days. ICU admissions during the ‘‘time at risk’’ were common
(60.8%), as well as the use of mechanical ventilation (47.8%).
Disease severity varied with a mean APACHE II score of 18.3.
Respiratory tract is the predominant site of growth (57.9%).
Secondary bacteremia occurred in 16 (7.8%) of the 205 episodes of
defined primary site other than primary bacteremia. In-hospital
and 30-day mortality rates were 37.3% and 33% respectively.
Comparing cases with controls, there was no difference in
predominant sex, but the cases were older (median [quartiles]: 73
[59; 79] vs. 65 [44.3; 77] years, p=0.02). More case patients were
with isolates from the respiratory tract (87.8% vs. 48.8%, p,0.001)
and more control patients were with isolates from the wound
(45.0% vs. 8.2%, p,0.001). Incidence of bacteremia was
comparable for cases and controls (12.2% vs. 8.8%, p.0.05).
The comorbidities were similar, except that there were more cases
with hepatic dysfunction (24.5% vs. 11.3%, p=0.02) and more
controls with musculoskeletal system and soft tissue surgeries
(30.0% vs. 8.2%, p=0.002). Case patients were with longer time at
risk (20 [12; 32.5] vs. 14 [9.3; 24] days, p=0.02), greater ICU
length of stay (11 [4.5; 19] vs. 2.5 [0; 10] days, p,0.001), more
ventilator days (10 [0; 16] vs. 0 [0; 8] days, p,0.001), and higher
APACHE II scores (24 [18; 31] vs. 17 [7;24], p,0.001).
The use of antimicrobial agents was reviewed, with doses and
days of use precisely verified. Case patients were exposed to more
vancomycin or teicoplanin (7 [0.5; 11] vs. 0 [0; 7.8] days,
p,0.001), imipenem or meropenem (10 [6;15] vs. 0 [0; 6] days,
p,0.001), and clindamycin (0 [0; 2] vs. 0 [0; 0] days, p=0.01). In
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cephalosporins (0 [0; 3] vs. 0 [0; 0] days, p=0.004) and gentamicin
(0 [0; 5] vs. 0 [0; 0] days, p=0.001) (Table 1). Among all the risk
factors identified in univariate analysis, exposure to carbapenems,
either imipenem or meropenem, was the only significant
independent one for the appearance of IR-MDRAB with
multivariate analysis (adjusted OR, 1.18; 95% CI, 1.09 to 1.27)
(Table 1).
Matched case control study. In order to exclude the
potentially confounding exogenous source of IR-MDRAB, 20
cases and 20 controls were selected from above for a matched case
control study. Selected cases and controls were matched for age,
location at the hospital, and date of hospitalization, presumably
with the same likelihood of acquiring exogenous IR-MDRAB.
Ages were matched for either below or above 55 and locations and
date of hospitalization were matched for admission to the same





p-Value p-Value Adjusted OR (95% CI)
Demographic parameters
Age, years 73 [59; 79] 65 [44.3; 77] 0.02 0.87 1.00 (0.97–1.03)
Male gender 35(71.4) 103(64.4) 0.36
Site of isolates
c
Respiratory tract 43(87.8) 78(48.8) ,0.001 0.37 2.36 (0.36–15.55)
Wound 4(8.2) 72(45.0) ,0.001 0.19 0.20 (0.02–2.17)
Bacteremia 6(12.2) 14(8.8) 0.58
Concomitant diseases
Hepatic dysfunction 12(24.5) 18(11.3) 0.02 0.30 1.78 (0.60–5.27)
Renal insufficiency 17(34.7) 48(30.0) 0.54
Chronic pulmonary disease 12(24.5) 28(17.5) 0.28
Cardiac disease 8(16.3) 17(10.6) 0.28
Cerebral vascular accident 19(38.8) 56(35.0) 0.63
Diabetes mellitus 15(30.6) 53(33.1) 0.74
Immune compromise 11(22.4) 25(15.6) 0.27
Malignancy
Hematological malignancy 0(0) 1(0.6) 1.0
Solid tumor with metastasis 3(6.1) 3(1.9) 0.14
Solid tumor, no metastasis 5(10.2) 5(3.1) 0.06
Surgery
Musculoskeletal/Soft tissue 4(8.2) 48(30) 0.002 0.67 1.43 (0.27–7.50)
Vital organs 8(16.3) 25(15.6) 0.91
Clinical conditions in TAR
Duration of TAR, days 20 [12; 32.5] 14 [9.3; 24] 0.02 0.77 1.00 (0.96–1.03)
ICU stay, days 11 [4.5; 19] 2.5 [0; 10] ,0.001 0.56 1.03 (0.94–1.13)
Ventilator use, days 10 [0; 16] 0 [0; 8] ,0.001 0.32 0.95 (0.87–1.05)
APACH II Score 24 [18; 31] 17 [7;24] ,0.001 0.43 1.02 (0.97–1.08)
Antibiotic exposure, days
c
Teicoplanin/Vancomycin 7 [0.5; 11] 0 [0; 7.8] ,0.001 0.70 0.99 (0.93–1.05)
1
st generation cephalosporins 0 [0; 0] 0 [0; 3] 0.004 0.27 0.86 (0.66–1.12)
Ceftriaxone 0 [0; 2] 0 [0; 0] 0.49
Imipenem/Meropenem 10 [6;15] 0 [0; 6] ,0.001 ,0.001 1.18 (1.09–1.27)
Gentamicine 0 [0; 0] 0 [0; 5] 0.001 0.76 1.03 (0.86–1.22)
Metronidazole 0 [0; 0] 0 [0; 2] 0.21
Clindamycin 0 [0; 2] 0 [0; 0] 0.01 0.68 1.04 (0.87–1.24)
Ciprofloxacin 0 [0; 3.5] 0 [0; 1.8] 0.15
NOTE.
aCategorical data are no.(%) of subject, continuous data are expressed as mean (SD) or median [quartiles].
bAll variables included in the final multivariable model are shown.
cOnly significant (p,0.05) and selected non-significant variables in univariate analysis are shown.
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were comparable, with respiratory tract predominated for both
groups (95% vs. 85%, p.0.05). Gender, comorbidities, ICU
length of stay, ventilator days, and APACHE II scores were also
similar. ‘‘Time at risk’’ was longer for cases than controls (21.5
[12.3; 37.3] vs. 10.5 [9.3; 19.3] days, p=0.02). Vancomycin or
teicoplanin (7.5 [1;17] vs. 0 [0; 7.8] days, p=0.03), imipenem or
meropenem (10 [8;16] vs. 0 [0; 7.8] days, p,0.001) and
ciprofloxacin (2 [0; 5] vs. 0 [0; 1.5] days, p=0.03) were more
often used in case patients. Multivariate analysis reached the same
conclusion that exposure to carbapenems was the only significant
independent risk factor for the appearance of IR-MDRAB
(adjusted OR, 1.48; 95% CI, 1.14 to 1.92) (Table 2).
Clinical outcomes
Mortality. The case patients had higher in-hospital and 30-
day mortality (57.1% vs. 31.3%, p=0.001 and 49.0% vs. 28.1%,
p=0.007). Case patients who survived were more likely with
isolates from the wound (19% vs. 0%, p=0.03). MDRAB
bacteremia was noted in 6 of the 49 cases, with 5 of them of
IR-MDRAB. In-hospital mortality for the 5 patients was 80% (4/
5). One patient of chronic ulcer infection survived, even without
specific antimicrobial therapy.
Risk factors for mortality. Associations between in-hospital
mortality and various conditions during the period of ‘‘time at risk’’
were analyzed for the 49 cases with appearance of IR-MDRAB.
Cases with mortality had more hepatic dysfunction (39.3% vs. 4.8%,
p=0.005), higher APACH II scores (mean6standard deviation,
27.667.4vs.2069,p=0.002),longerventilatordays(11[9;18.8]vs.
3[ 0 ;1 3 ]d a y s ,p=0.02), less exposure to oxacillin (p=0.02), and
shorter ‘‘time at risk’’ (15.5 [10; 22.5] vs. 24 [19; 35.5] days,
p=0.004). However, in-hospital mortality was significantly
associated only with the length of ‘‘time at risk’’ in multivariate
analysis (adjusted OR, 0.9; 95% CI, 0.83 to 0.98, logistic regression
of backward stepwise procedure). The sooner the IR-MDRAB
emerged, the less chance the case patients would survive.
Outcome with specific treatment. Combination of
carbapenem and sulbactam is one of the recommended
regimens for IR-MDRAB eradication, based on the in vitro
synergism and the in vivo effectiveness in an animal model [21,22].
Forty two case patients who survived for more than 3 days after
emergence of IR-MDRAB were included for analysis of treatment
outcome with specific regimens. Patients who received the
combination of carbapenem and sulbactam for at least 3 days
had higher in-hospital mortality but this was with no statistical
significance (6/8 75% vs. 16/34 47.1%, p=0.24).





p-Value p-Value Adjusted OR (95% CI)
Demographic parameters
Male gender 12(60) 14(70) 0.51
Site of isolates
c
Respiratory tract 19(95) 17(85) 0.61
Wound 1(5) 1(5) 1.0
Bacteremia 2(10) 1(5) 1.0
Concomitant disease
c
Renal insufficiency 7(35) 5(25) 0.49
Chronic lung disease 5(25) 8(40) 0.31
Diabetes mellitus 7(35) 13(65) 0.06
Immune compromise 6(30) 5(25) 0.72
Solid tumor 3(15) 1(5) 0.61
Clinical conditions in TAR
Duration of TAR, days 21.5 [12.3; 37.3] 10.5 [9.3; 19.3] 0.02 0.27 0.96 (0.90–1.03)
ICU stay, days 12.5 [7.5; 21.8] 10 [8.3; 16] 0.43
Ventilator use, days 11.5 [6; 20.3] 8 [2.3; 14] 0.18
APACH II Score 26.80 (8.7) 24.65 (8.0) 0.42
Antibiotic exposure, days
c
Teicoplanin/Vancomycin 7.5 [1;17] 0 [0; 7.8] 0.03 0.08 0.87 (0.75–1.01)
Ceftriaxone 0 [0; 0] 0 [0; 5] 0.08
Imipenem/Meropenem 10 [8;16] 0 [0; 7.8] ,0.001 0.003 1.48 (1.14–1.92)
Clindamycin 0 [0; 2] 0 [0; 1.5] 0.44
Ciprofloxacin 2 [0; 5] 0 [0; 1.5] 0.03 0.70 1.05 (0.81–1.37)
NOTE.
a Categorical data are no.(%) of subject, continuous data are expressed as mean (SD) or median [quartiles].
bAll variables included in the final multivariable model are shown.
cOnly significant (p,0.05) and selected non-significant variables in univariate analysis are shown.
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Our study reached the conclusion that the only independent risk
factor for appearance of IR-MDRAB in patients formerly with IS-
MDRAB is the use of carbapenem. The ‘‘time at risk’’, the period
of time at risk for appearance of IR-MDRAB, is a very important
confounding factor to be adjusted because the probability of
appearance increases with the length of the time [16]. In our study
the ‘‘time at risk’’ was precisely defined for each individual patient
and analyzed. ‘‘Time at risk’’ is also the critical period of time
when physicians have to make decision on whether to eradicate
IS-MDRAB with carbapenems. Antimicrobial selective pressure
and clinical parameters, such as APACHE II score, ICU stay, and
ventilator use were focused on the period of ‘‘time at risk’’.
Although old age, respiratory tract isolates, prolonged ICU stay,
prolonged ventilator use and high APACHE II score were all
significant risk factors in univariate analysis, multivariate analysis
revealed carbapenem only as the significant independent risk
factor. Some APACHE II score data was not complete,
particularly for those not staying in the ICU. Low scores may
have been underestimated and then the high scores of critically ill
patients were relatively over-estimated. Even with over-estimation,
APACHE II score still could not stand out as an independent risk
factor in the multivariate analysis.
The clinical impact of MDRAB is controversial. Some studies
showed prolonged hospital and ICU stays and increased mortality;
however, there was no attributable mortality if severity of illness
and underlying diseases had been controlled [12,23]. Our case
patients had higher mortality in univariate analysis and the length
of ‘‘time at risk’’ was the only significant independent risk factor
for mortality in multivariate analysis. That is, patients with IR-
MDRAB were more likely to incur mortality if IR-MDRAB had
appeared in a faster pace. This result implied unfavorable outcome
with appearance of IR-MDRAB.
Our samples were clinical, instead of surveillance, isolates. All
cultures were requested by clinicians based on clinical discretion.
Studies with surveillance isolates may reach different conclusions.
However, clinical isolates are more clinically relevant and will
provide insightful information for clinical practice. The serial
isolates were from the same body sites of each individual patient. It
implied possibility of either susceptibility conversion from formerly
imipenem susceptible strains to resistance or resistant strain
selection. It was also possible that some resistant strains were
acquired from an exogenous source. Our effort for this problem
was to select cases and controls for a matched control study. The
selected cases and controls, matched for age and location and date
of hospitalization, were with similar theoretical likelihood of
acquiring resistant strain from the environment. Besides, IR-
MDRAB on subsequent cultures of less than 7 days were excluded
by our arbitrary definition that they were more likely from
exogenous sources.
It is interesting to understand the microbiology behind this
clinical phenomenon. Acinetobacter species possessed a wide array of
b-lactamases and other enzymes for carbapenem resistance,
encoded by transposable elements, plasmids or chromosomes
[24]. One possibility was that antimicrobial selective pressure
caused conversion of the sensitive clones, either by mutation or by
induced expression of resistance elements which had been kept
silent otherwise. It is also possible that carbapenem-resistant
Acinetobacter expanded from undetectable minority to predominant
clones as carbapenem had eradicated the majority of sensitive
ones. Although our data somehow suggested an inducible
mechanism for carbapenem resistant strains to emerge under the
selective pressure of carbapenem, there has been so far no
microbiological evidence linking any resistance mechanism to such
a phenomenon.
Numerous reports suggested causal associations between
quantities of antibiotic used and the development of resistance
with hospital-wide or nationwide data [25,26]. The direct
relationship between antibiotic consumption and emergence of
resistance on individual patient was not clear. Our conclusion that
carbapenem use was the only independent risk factor for
appearance of IR-MDRAB exemplified a dilemma in clinical
practice. We have to use carbapenem for eradication of IS-
MDRAB and it actually causes the emergence of IR-MDRAB at
the same time. Other antimicrobial agents should be evaluated for
the efficacy of eradicating IS-MDRAB. Effective alternative
therapy would decrease emergence of IR-MDRAB. It can not
be overemphasized that the decision to eradicate IS-MDRAB with
carbapenem has to be exercised with caution. Judicious use of
carbapenem with antibiotics stewardship programs would be the
most effective measure to avoid the emergence of imipenem
resistant MDRAB and the associated unfavorable outcome.
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